Doripenem
- Atc Codes:J01DH04
- CAS Codes:148016-81-3
- PHARMGKB ID:148016-81-3
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Doribax; Belgium: Doribax; Bulgaria: Doribax; Cyprus: Doribax; Czech Republic: Doribax; Denmark: Doribax; Estonia: Doribax; Finland: Doribax; France: Doribax; Germany: Doribax; Greece: Doribax; Hungary: Doribax; Ireland: Doribax; Italy: Doribax; Latvia: Doribax; Lithuania: Doribax; Malta: Doribax; Netherlands: Doribax; Poland: Doribax; Portugal: Doribax; Romania: Doribax; Slovakia: Doribax; Slovenia: Doribax; Spain: Doribax; Sweden: Doribax; UK: Doribax.
North America
Canada: Doribax; USA: Doribax.
Latin America
Argentina: Doribax.
Asia
Japan: Finibax.
Drug combinations
Chemistry
Doripenem: C~15~H~24~N~4~O~6~S~2~. Mw: 420.50. (1) 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[(3S,5S)-5-[[(aminosulfonyl)amino]methyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, (4R,5S,6S)-; (2)(+)-(4R,5S,6S)-6-[(1R)-1-Hydroxyethyl]-4-methyl-7-oxo-3-[[(3S,5S)-5-[(sulfamoylamino)methyl]-3-pyrrolidinyl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid. CAS-148016-81-3 (2005).
Pharmacologic Category
Antibacterials; Miscellaneous β-Lactams; Carbapenems. (ATC-Code: J01DH04).
Mechanism of action
Synthetic carbapenem β-lactam antibiotic. Doripenem exerts its bactericidal activity by inhibiting cell wall synthesis in susceptible organisms. Has a broad spectrum of activity and is active in vitro against many Gram-negative and Gram-positive aerobic and anaerobic bacteria.
Therapeutic use
Used for the treatment of complicated intra-abdominal infections caused by susceptible Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. caccae, B. thetaiotaomicron, B. uniformis, B. vulgatus, Streptococcus intermedius, Streptococcus constellatus, or Peptostreptococcus micros. Also used for the treatment of complicated urinary tract infections (including pyelonephritis) caused by susceptible E. coli (including cases with concurrent bacteremia) or susceptible K. pneumoniae, Proteus mirabilis, Ps. aeruginosa, or Acinetobacter baumannii.
Pregnancy and lactiation implications
Adverse events not observed in animal studies. No adequate, well-controlled studies completed in pregnant women. It is not known if doripenem is excreted into breast milk. Use with caution when administered during lactation.
Unlabeled use
Treatment of nosocomial pneumonia.
Contraindications
Known serious hypersensitivity to doripenem or other carbapenems (e.g. imipenem, ertapenem, meropenem). Anaphylactic reactions to β-lactam antibiotics.
Warnings and precautions
Serious hypersensitivity reactions, including anaphylaxis, and skin reactions reported in patients receiving β-lactams. Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea and pseudomembranous colitis. Use with caution in renal impairment. Levels of valproic acid may be decreased (potential for breakthrough seizures). Administer via I.V. infusion only.